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RON, a cDNA homologous to the hepatocyte growth
factor (HGF) receptor gene (MET), encodes a putative
tyrosine kinase. Here we show that the RON gene is
expressed in several epithelial tissues as well as in
granulocytes and monocytes. The major RON tran-
script is translated into a glycosylated single chain
precursor, cleaved into a 185 kDa heterodimer
(pl85RON) of 35 (a) and 150 kDa (1) disulfide-linked
chains, before exposure at the cell surface. The Ron 1-
chain displays intrinsic tyrosine kinase activity in vitro,
after immunoprecipitation by specific antibodies. In
vivo, tyrosine phosphorylation of pl85RON is induced
by stimulation with macrophage stimulating protein
(MSP), a protease-like factor containing four 'kringle'
domains, homologous to HGF. In epithelial cells,
MSP-induced tyrosine phosphorylation of p185RON is
followed by DNA synthesis. p185RON is not activated
by HGF, nor is the HGF receptor activated by MSP
in biochemical and biological assays. p185RON is also
activated by a pure recombinant protein containing
only the N-terminal two kringles of MSP. These data
show that p185RON is a tyrosine kinase activated by
MSP and that it is member of a family of growth
factor receptors with distinct specificities for structur-
ally related ligands.
Key words: growth factor receptors/HGF/MET oncogene/
MSP/RON tyrosine kinase
Introduction
Receptor type protein tyrosine kinases play a critical role
in the control of cell growth and differentiation mediating
the response to extracellular signals such as peptide
hormones and growth factors (Schlessinger and Ullrich,
1992; Fantl et al., 1993). The common architecture of
these molecules includes an extracellular ligand binding
domain, a hydrophobic membrane spanning domain and
a large cytoplasmic portion which carries the catalytic
function. All receptor type tyrosine kinases share a con-
served catalytic domain which is found in combination
with a range of different extracellular domains (Hanks
et al., 1988; Yarden and Ullrich, 1988). The latter activate
the catalytic domain in response to the binding of specific
extracellular ligands.
There are several sub-families of receptor tyrosine
kinases; ligands have only been assigned to a few of these.
For others, the receptor function has been postulated on
the basis of structural similarities to known receptors (for
a review see Hunter and Lindberg, 1994).
We previously showed that the protein encoded by the
MET proto-oncogene (pl9OMEq) is the prototype of a
family of tyrosine kinase receptors on the basis of specific
features. These include: (i) the heterodimeric subunit
structure (Giordano et al., 1989a), (ii) two neighbouring
tyrosine residues in the kinase domain, responsible for
regulation of the enzymatic activity upon autophosphoryl-
ation (Ferracini et al., 1991; Longati et al., 1994), (iii) a
bidentate docking site in the C-terminal tail which mediates
high-affinity interactions with multiple SH2-containing
signal transducers (Ponzetto et al., 1994).
The physiological role of pl9OmET was unveiled when
it was identified as the receptor for hepatocyte growth
factor (HGF) (Bottaro et al., 1991; Naldini et al., 1991a,b).
HGF is a large protein, made of an a-chain, containing
four kringle domains, and a disulfide-linked 13-chain,
endowed with strong homology with serine proteases,
but devoid of catalytic activity (Miyazawa et al., 1989;
Nakamura et al., 1989). HGF controls an array of complex
biological functions, including proliferation, motility and
differentiation of epithelial cells (Gherardi and Stoker,
1991).
Recently the MET gene family acquired two new
putative members, after the isolation of the cDNA for
avian c-sea (Huff et al., 1993) and for human RON
(Ronsin et al., 1993). The deduced amino acid sequences
show significant homologies with the Met protein and
include the above listed structural features of the HGF
receptor. Interestingly, two independent reports pointed
out the existence of one protein which is related to HGF.
This protein, called 'HGF-like' (Han et al., 1991) or
macrophage stimulating protein (MSP; Skeel et al., 1991;
Yoshimura et al., 1993) shares with HGF the overall four
kringle/protease-like structure.
In this paper we show that RON encodes an hetero-
dimeric transmembrane glycoprotein (p1 85RON), expressed
in a variety of tissues, mainly of epithelial origin, and in
monocytes. p185RON is endowed with intrinsic tyrosine
kinase activity that is stimulated by MSP.
Results
Cloning and analysis of the RON cDNA
In an effort to identify new members of the MET receptor
family, we performed a reverse-transcriptase polymerase
chain reaction analysis on RNAs extracted from different
cell lines and tissues, following the method of Raz
3524 ©Q) Oxford University Press
Activation of the Ron receptor by MSP
305-309
KRRRR
958-982
tm
1089-1352 1400
tk
A
884-932
B
S-S
I
YY
1238,1239
[M yy
1353,1360
Fig. 1. (A) Schematic representation of the open reading frame of the RON cDNA, isolated from the GTL-16 cell line. The consensus sequence for
the proteolytic cleavage generating the xp-heterodimer (KRRRR), the transmembrane (tm) and the tyrosine kinase (tk) domains are indicated. The
base pairs 884-932 are deleted in the variant A-RON. (B) Schematic representation of the mature heterodimeric Ron protein. a, light chain of 35
kDa. P, heavy chain of 150 kDa. The number and the location of the disulfide (-S-S-) bond(s) are unknown. The conserved critical tyrosine residues
of the cytoplasmatic domain are indicated.
et al. (1991). Degenerate oligonucleotide primers designed
according to sequences situated in the subdomains VI and
X of tyrosine kinases (Hanks et al., 1988) were used.
Sequences of the several clones obtained were compared
with the EMBL Database. One of the cDNA fragments
(384 bp in length) matched the sequence of RON, a newly
identified homologue of human MET (Ronsin et al., 1993).
Using this as a probe, full-length cDNA for RON was
obtained from a library derived from the GTL16 gastric
carcinoma cell line (Giordano et al., 1993). The cDNA
showed complete identity with the previously reported
RON sequence (Ronsin et al., 1993). A variant diverging
by an in-frame 49 amino acid deletion in the extracellular
domain, was also identified. The boundaries of the deletion
were located between positions Glu883-Tyr884 and
positions Gln932-Val933 (Figure 1).
Expression of the RON gene
The expression of RON was examined in a number of
human tissues and cell lines by Northern blot analysis
of total RNA, using a cDNA probe encompassing the
entire coding sequence. RNAs from human tissues were
prepared from fresh samples harvested from organ donors.
A 5.0 kb mRNA was the major detectable RON transcript;
a 2.0 kb mRNA was also observed. As shown in Figure
2, significant levels of mRNA were found in colon, skin,
lung and bone marrow. Among blood cells, granulocytes
were strongly positive whilst lymphocytes were negative.
Adherent monocytes showed a detectable expression of
RON mRNA. In a panel of cell lines, the expression
of RON was studied at both RNA and protein level.
Epithelial cell lines derived from gastric, pancreatic and
mammary carcinoma and the hematopoietic cell lines
HL-60 and K562 were positive (Figure 3A and B).
Structure and biosynthesis of the Ron protein
The RON cDNA was expressed in COS-1 cells under
control of the adenovirus late promoter. The translation
product was analysed using antibodies raised against a
GST fusion protein containing 41 C-terminal amino acids.
In Western blots, Ron antibodies reacted with two proteins
(Figure 4A). One showed an apparent molecular mass of
185 kDa (pl85R0N) when Western blots were performed
under non-reducing conditions. After reduction this molec-
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Fig. 2. Northern analysis of RON expression in normal human tissues.
Twenty micrograms of total cellular RNA were loaded per lane. A
major 5.0 kb transcript is evident and a 2.0 kb form is also detectable
in most samples. A probe for the housekeeper gene glyceraldehyde
3-phosphate dehydrogenase (GADPH) was used to evaluate the
amount of mRNA transferred to filters. The Northern blot was exposed
for 60 h. The molecular mass of the hybridizing bands was estimated
using ribosomal RNAs as internal standards.
ule shifted to an apparent molecular mass of 150 kDa. A
second molecule with an apparent molecular mass of 170
kDa (prl70) showed the same electrophoretic mobility
under both non-reducing and reducing conditions. Meta-
bolic labelling with [3H]glucosamine (Figure 4B), followed
by anti-Ron immunoprecipitation, showed that p1 85R0N is
an heterodimer of two chains linked by disulfide bonds:
3, of 150 kDa and a, of 35 kDa.
prl70 behaves as the immature precursor of the ax
heterodimer, as shown in time-course experiments after
transfection of RON cDNA in COS-1 cells (Figure 5).
After 24 h prl70 accumulated and was the only band
detectable in Western blots by anti-Ron antibodies under
reducing conditions. In the following hours the 150 kDa
,-chain became progressively detectable as the amount of
prl70 decreased. It should be noted that in these experi-
ments the a-chain was not labelled since the antibodies
recognize C-terminal epitopes localized only on the P-
chain. In cells expressing physiological amounts of endo-
genous Ron, only the mature (cleaved) pl85R0N was
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Fig. 3. Northern and Western analysis of RON expression. (A) Northern analysis of RON expression in a panel of assorted human cell lines (seeMaterials and methods). As in the case of tissues, a major 5.0 kb and a minor 2.0 kb transcript were observed. The amount of RNA transferred andthe molecular mass were estimated as in Figure 2. (B) Western analysis on anti-Ron immunoprecipitates from lysates of human cell lines. Proteinswere separated in reducing conditions, transferred and probed as described in Materials and methods. As described below, the major band is the Ron:-chain. The minor band, with higher molecular mass, is the immature single chain precursor. Positions of molecular mass markers are indicated.
exposed at the cell surface, as shown by domain-selective
cell surface biotinylation (Crepaldi et al., 1994b). In
COS-1 cells overexpressing the transfected RON cDNA a
fraction of uncleaved protein was found at the cell surface
(Figure 6).
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The Ron protein is a functional tyrosine kinase
The intracellular portion of the Ron ,-chain contains
canonical motifs identifying a putative tyrosine kinase
domain (Hanks et al., 1988; Ronsin et al., 1993). In order
to assess whether this molecule is indeed a functional
kinase, recombinant p185R0N, immunoprecipitated from
COS-1 cells, and native p185RIN, immunoprecipitated
from GTL-16 cells, were incubated with [y-32P]ATP in
the presence of Mn ions. It is known (Yarden and Ullrich,
1988; Naldini et al., 1991c) that under these conditions
the antibody induced dimerization activates tyrosine kinase
receptors leading to autophosphorylation, even in the
absence of a specific ligand. p1 85R0N autophosphorylated
on tyrosine on its ,-chain (Figure 7). Phosphorylation
occurred on tyrosine residues, as demonstrated by alkali
resistance and by phosphoamino acid analysis (data not
shown). The tyrosine phosphatase inhibitor sodium ortho
vanadate, added to the cells 10 min before lysis, enhanced
the autophosphorylation of p185R0N*
The Ron protein is phosphorylated on tyrosine in
response to MSP
The above data show that p185RON is a tyrosine kinase
with putative receptor functions. As discussed, the protein
shares structural similarities with the HGF receptor. Inter-
estingly, one protein related to HGF has been recently
identified. This molecule was called 'HGF-like' or MSP
(Han et al., 1991; Skeel et al., 1991; Yoshimura et al.,
1993).
To investigate the possible functional relationship
between p1 85R0N and MSP, we challenged cells expressing
RON with recombinant MSP. Tyrosine phosphorylation of
the p1 85RON ,-chain was assessed by Western blotting
with anti-phosphotyrosine antibodies of immunoprecipi-
-(Yi-chain
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Fig. 4. Heterodimeric structure of the Ron protein. (A) Westernblotting of anti-Ron immunoprecipitates from lysates of transfectedCOS-1 cells. The analysis was perforrned as in Figure 3B, either innon-reducing (n.r.) or in reducing (r.) conditions. (B) [3H]Glucosaminein vivo labelling of RON-transfected COS-1 cells. Proteins eluted from
immunoprecipitates made with Ron antibodies from metabolicallylabelled cells were separated by SDS-PAGE under non-reducing (n.r.)
or reducing (r.) conditions. Arrows indicate the uncleaved precursor(prl7ORON), the mature a1x heterodimer (pl85RON), the 150 kDa P-chain and the 35 kDa a-chain. In the Western blot shown in (A), thea-chain is not visible, as the antibodies recognize an epitope of the 5-chain.
tates made with specific Ron antiserum. The experiments
were performed either on COS- 1 cells, transientlyexpressing high levels of the recombinant protein, or oncells expressing the native protein. In RON transfected
COS- 1 cells a basal level of f-chain tyrosine phosphoryla-tion was observed as a consequence of the overexpression(Longati et al., 1994). On the other hand, in T47D
mammary carcinoma cells, expressing the native p1 85RON,the basal level of ,8-chain tyrosine phosphorylation was
undetectable. Cells were treated with conditioned medium
harvested from mock-transfected 293 cells (controls) or
from cells transfected with MSP cDNA, cloned as
described in Materials and methods. It should be noted
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Fig. 5. Biosynthesis of the Ron protein. Western analysis on anti-Ron
immunoprecipitates from RON-transfected COS-1 cells, lysed 24, 48,
72 or 96 h after transfection. The blot was performed as in Figure 3B.
At one day after transfection only the prl70RON precursor is
detectable. In the following hours an increasing amount of mature
Ron 3-chain accumulates. The mature form is predominant 4 days
after transfection. As in Figure 4A, the a-chain is not visible, because
of the specificity of the antibodies.
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Fig. 6. Exposure of pl85RON at the cell surface. Mock-transfected cells
(COS-1), RON-transfected cells (COS-1/RON), GTL-16 cells and
T47D cells, expressing endogenous RON, were subjected to domain-
selective cell surface biotinylation. Proteins from cell lysates were
immunoprecipitated with Ron antibodies, separated by SDS-PAGE
under non-reducing (n.r.) or reducing (r.) conditions and transferred
to nitrocellulose. Biotinylated proteins were visualized by streptavidin
-HRP, followed by ECL (enhanced Chemiluminescence kit). Under
these conditions biotin labelled the 185 kDa heterodimer and both the
150 kDa ,B-chain and the a-chain (arrows). A fraction of uncleaved
protein (uncl.) is labelled only in COS-l cells overexpressing RON.
that recombinant MSP is secreted as single chain precursor
(Yoshimura et al., 1993). By analogy with what has been
described for the HGF precursor (Naldini et al., 1992), in
vitro maturation of MSP into the biologically active ap
heterodimer was obtained by serum-dependent proteolytic
cleavage (see Materials and methods; Wang et al., 1994).
Recombinant MSP stimulated tyrosine phosphorylation of
the pI85RON n-chain in both RON-transfected COS-1 cells
(Figure 8A) and in T47D cells (Figure 8B). The medium
Fig. 7. Ron is a functional protein tyrosine kinase. Proteins from
lysates of RON-transfected COS-1 cells or from GTL-16 cells, either
treated with sodium orthovanadate (+) or untreated (-) were
immunoprecipitated with Ron antibodies. A kinase assay was
performed on immunocomplexes, as described in Materials and
methods. Proteins were separated by SDS-PAGE under reducing
conditions. Gels were alkali treated, dried and exposed for
autoradiography with intensifying screens. A major tyrosine
phosphorylated band of 150 kDa, corresponding to the 5-chain of Ron
is evident; tyrosine phosphorylation was enhanced in samples from
cells pretreated with vanadate prior to extraction.
from mock-transfected 293 cells neither induced p1 85R0N
phosphorylation in T47D cells nor altered the basal
p185R0N phosphorylated status in COS-1 transfectants.
p185 /ON is not cross-activated by HGF
Given the structural similarities between p185R0N and the
HGF receptor on the one hand, and between MSP and
HGF on the other, their possible cross-reactivity was
investigated. No effects on tyrosine phosphorylation of
p185R0N was observed after HGF treatment of cells
expressing either the native or the transfected receptor
(Figure 8A and B). The lack of cross-reactivity was
confirmed in biological assays. It is known that MSP
stimulates a chemotactic response to C5a in macrophages
(Yoshimura et al., 1993). HGF, also known as 'scatter
factor', stimulates cell motility of epithelial cells (Naldini
et al., 1991b; Weidner et al., 1991; Giordano et al., 1993).
In a Boyden chamber, supernatants containing recombinant
MSP were found to stimulate monocyte migration, but
were ineffective on A549 epithelial cells. Conversely,
recombinant HGF stimulated migration of A549 but not
of monocytes (Figure 9). Moreover, preincubation of
monocytes with HGF had no inhibitory effect on MSP
activity. Similarly, MSP did not interfere with HGF
stimulation of A549 cells (data not shown).
p185flONphosphorylation by MSP is followed by
DNA synthesis
Tyrosine phosphorylation of growth factor receptors activ-
ates basic intracellular signalling mechanisms, which trans-
duce growth factor signals to the nucleus. We tested DNA
synthesis in T47D epithelial cells, where MSP induces
specific tyrosine phosphorylation of p1 85R0N. Confluent
and quiescent monolayers of T47D were
incubated with the conditioned medium of mock- and
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Fig. 8. Ron is phosphorylated on tyrosine in response to MSP. RON-transfected COS-1 cells (A) or T47D cells (B) were stimulated with culture
media of cells transfected either with an empty vector (EMPTY) or with a vector containing MSP or HGF cDNA. Cell lysates were
immunoprecipitated with Ron antibodies; immunocomplexes were Western blotted and probed with monoclonal phosphotyrosine antibodies (anti P-
Tyr) or with anti-Ron antibodies and visualized by ECL. MSP-induced tyrosine phosphorylation of the Ron n-chain is detectable both in Ron
transfected COS-1 cells and in T47D cells expressing the endogenous protein. Tyrosine phosphorylation of the uncleaved precursor (uncl.) is only
observed in COS-1 cells overexpressing RON.
MSP-transfected 293 cells and with the conditioned
medium of cells transfected with HGF cDNA. MSP
induced a significant increase in DNA synthesis, measured
as [3H]thymidine incorporation (Figure 10). Again, no
cross-reactivity was observed with HGF, which neither
induced phosphorylation of p1 85R0N nor stimulated DNA
synthesis. It should be noted that the T47D cell line used
in these experiments does not express the HGF receptor,
as assessed by specific anti-Met antibodies and RT-PCR
(data not shown).
p185RONis activated by the N-terminal two
kringles of MSP
It has been shown previously that the binding activity of
HGF to its receptor is conveyed by a functional domain
located in the N-terminal portion of the molecule, including
the first two 'kringles' (Matsumoto et al., 1991; Hartmann
et al., 1992; Lokker et al., 1992; Lokker and Godowski,
1993). Therefore, we tested the N-terminal region of MSP
expressed as a fusion protein with a C-terminal fragment of
the human IgG-yI heavy chain (MSP-NK2). MSP-NK2
contains the first two kringles of MSP and was purified to
homogeneity by affinity chromatography on immobilized
protein A (see Materials and methods). As shown in
Figure 1lA, MSP-NK2 stimulated, in a dose-dependent
manner, tyrosine phosphorylation of p185RON, expressed
in COS-1 cells. The effect was specific, since MSP-NK2
did not stimulate a chimeric receptor made of the
intracellular tyrosine kinase domain of Ron linked to the
extracellular domain of the nerve growth factor (NGF)
receptor (TRK) (Figure 11B).
Discussion
In recent years new members of the protein tyrosine kinase
family have been discovered at an increasing rate. Some of
them have been classified as putative receptors according
to the structural features deduced from their cDNAs
(Schlessinger and Ullrich, 1992; Hunter and Lindberg,
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Fig. 9. MSP and HGF do not cross-activate their receptors in
biological assays. A-549 cells (1.5 X 105) or human blood monocytes,
purified by Ficoll density gradient centrifugation and adherence, were
plated in the upper chamber of a blind-well Boyden chamber equipped
with a porous polycarbonate filter and assayed for migration.
Conditioned media from cells either transfected with an empty vector
(EMPTY) or containing the HGF or MSP cDNAs were tested at 1:10
dilution. For assaying the chemotactic response of A-549 cells,
conditioned media were added in the bottom chamber. For assaying
the stimulation of monocyte migration towards the chemoattractant
(C5a) placed in the bottom chamber, conditioned media were added in
the upper chamber. Both assays were performed in the presence of 5%
complement-inactivated fetal calf serum. Cells which migrated to the
lower side of the filter were stained and counted. Similar results were
obtained with higher dilution of the culture media.
1994). In several instances, the tyrosine kinase activity of
the putative receptors has been demonstrated biochem-
ically. In fewer cases the cognate ligands have been
identified: Steel factor for Kit (Nocka et al., 1990), NGF
for Trk (Cordon-Cardo et al., 1991; Kaplan et al., 1991),
HGF for Met (Bottaro et al., 1991; Naldini et al., 1991a)
and heregulin for HER4 (Plowman et al. 1993).
A putative tyrosine kinase receptor is RON, whose
sequence has been derived from a cDNA recently cloned
from a human keratinocyte cDNA library (Ronsin et al.
1993). We isolated the same cDNA from a human gastric
G.Gaudino et al.
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carcinoma library (Giordano et al., 1993), using a partial
clone obtained by RT-PCR as a probe and degenerate
oligonucleotide primers derived from the tyrosine kinase
domain of the HGF receptor sequence (MET). The RON
cDNA encodes a protein of 1400 amino acids which
shares an overall structural homology with the HGF
receptor and displays 63% sequence identity in the cata-
lytic domain.
By Northern analysis we found that Ron is expressed
as a major 5.0 kb transcript in epithelial tissues and cell
lines. Notably, the gene is also expressed by blood
granulocytes and monocytes. The tissue distribution of
this putative tyrosine kinase receptor is reminiscent of the
expression pattern of the HGF receptor (Di Renzo et al.,
1991; Prat et al., 1991).
We show that the product of the Ron gene is a
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Fig. 10. MSP stimulates DNA synthesis of epithelial cells. T47D cells,
cultured on 24-well plates, were incubated with conditioned medium
of cells transfected either with an empty vector (EMPTY), or with a
vector containing the HGF or MSP cDNA. Media were used at 1:5
dilution. 3H-Thymidine incorporation was evaluated as described in
Materials and methods. The data shown are the average (± SD) of
replicate wells (n=3) from a typical experiment.
glycosylated protein of 185 kDa (p1 85RON). The molecule
is an heterodimer of two chains: a (35 kDa) and f (150
kDa). The two chain structure is very similar to that of
the HGF receptor (Giordano et al., 1989a). We also show
that, as for the HGF receptor (Giordano et al., 1989b),
p185RON is synthesized as a single chain precursor
(prl70RON), which is converted into the mature form
by proteolytic cleavage. A conserved site for furin-like
proteases (Mark et al., 1992) is present in the precursors
of both molecules between residues 305-309 and 303-
307, respectively (Figure 1). By domain-selective surface
biotinylation we found that the mature heterodimeric form
is delivered to the cell surface, while the unprocessed
single chain precursor is not. Thus, as in the case of the
HGF receptor, proteolytic cleavage of the precursor takes
place before the appropriate subcellular localization
(Crepaldi et al., 1994a,b). In non-physiological conditions,
such as in cells overexpressing exogenous RON under
control of a strong promoter, the subcellular machinery
responsible for proteolytic cleavage is overloaded. This
leads to the abnormal expression of uncleaved pI85R0N
at the cell surface. As in the case of cells overexpressing
MET (Mondino et al., 1991; Naldini et al., 1991a), the
uncleaved p1 85RON is capable of responding to ligand
stimulation.
The tyrosine kinase of p1 85RON can be activated either
in vitro by immunoprecipitation with bivalent antibodies,
or in vivo by overexpression in transfected cells. Both
conditions are known to trigger kinase activity through
receptor dimerization and subsequent transphosphorylation
(Honegger et al., 1988; Lammers et al., 1990; Naldini
et al., 1991c). One characteristic feature of the kinase
domain of p185RON are two tyrosines at position 1238 and
1239 (see Figure 1) conserved in the HGF and in the
insulin receptor (Tornqvist et al., 1987). It has been
shown that these are the major autophosphorylation sites
(Ferracini et al., 1991) and are responsible for upregulation
of the kinase activity in the HGF receptor (Longati et al.,
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Fig. 11. The two N-terminal kringles of MSP stimulate phosphorylation of Ron via its extracellular domain. COS-1 cells were transfected with RON
cDNA (A), or with a chimeric cDNA containing the extracellular domain of TRK fused with the intracellular domain of RON (B). Cells were
stimulated with the indicated concentrations of highly purified fusion protein MSP-NK2, containing the first two N-terminal kringle domains.
Controls included unstimulated cells (n.s.) and cells stimulated with nerve growth factor. Cell lysates were immunoprecipitated with Ron antibodies,
Western blotted, probed with monoclonal phosphotyrosine antibodies and visualized by ECL. (A) Tyrosine phosphorylation of the Ron ,-chain by
MSP-NK2 is dose-dependent. As observed in Figure 8A, the uncleaved Ron protein (uncl.) is modestly phosphorylated. (B) MSP-NK2 fails to
stimulate tyrosine phosphorylation of the chimeric receptor. As reported by others (Weidner et al., 1993), the Trk chimera migrates as a broad band
(vertical bar). In both panels gels were run in reducing conditions.
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1994). It is thus conceivable that the Ron tyrosine kinase
is regulated by the same auto-catalytic mechanism operat-
ing in the HGF and insulin receptors (Lammers et al.,
1990; Naldini et al., 1991c).
The high degree of homology with the HGF receptor
prompted us to test the hypothesis that p1 85R0N could be
the receptor for a recently isolated molecule closely related
to HGF. This protein, called 'HGF-like' (Han et al., 1991)
or MSP (Skeel et al., 1991; Yoshimura et al., 1993), is
an heterodimer of a heavy chain of 53 kDa (a) and a
light chain of 25 kDa (3). The MSP sequence includes
four kringle domains, found also in HGF and in several
proteins of the blood coagulation cascade. Among these,
the highest homology (45% identity) has been found
between MSP and HGF. Based on expression studies, the
liver appears to be the main source of MSP. Both the
MSP and the RON gene map to human chromosome 3p2.1
(Han et al., 1991; Ronsin et al., 1993). Colocalization
also occurs in the case of the HGF and the HGF receptor
(MET) genes, both located in the long arm of chromosome
7, within the region qll.2-q21.1 (Dean et al., 1985;
Weidner et al., 1991; Saccone et al., 1992). The biological
activity of MSP is largely unknown: the factor was
named after its ability to confer responsiveness to the
chemoattractant C5a to mouse resident peritoneal macro-
phages (Skeel et al., 1991).
We now show that recombinant MSP is able to stimulate
tyrosine phosphorylation of p1 85R0N, whether endogenous
or transfected. Moreover, MSP behaves as a mitogen
in epithelial cells, where it induces p185RIN tyrosine
phosphorylation. In the absence of available purified MSP,
and therefore of cross-linking data, one cannot in principle
exclude the possibility that MSP may interact with another
molecule which in turn activates p1 85RNvia heterodimeri-
zation and transphosphorylation (Peles et al., 1992; Wen
et al., 1992; Plowman et al., 1993). However, trans-
phosphorylation by an unidentified receptor did not occur
in the case of the TRK-RON chimera, sharing the
intracellular domain with p1 85R0N. Moreover, the striking
similarities between Ron and the HGF receptor (Met) on
one side, and between MSP and HGF on the other, strongly
suggest that MSP functions as a ligand for p1 85R0N. Thus
MET and RON encode two members of a family of
receptors for structurally-related ligands.
A variable degree of cross-reactivity among ligands for
receptors of the same subfamily has been described in
the case of receptors for the nine FGFs (Bellot et al.,
1991; Ueno et al., 1992), PDGF A and B (Heldin and
Westermark, 1989), VEGF/VPF (Devries et al., 1992;
Galland et al., 1993), neurotrophins (Barbacid, 1993),
EGF, TGFa and the heregulin family (Carpenter and
Wahl, 1990; Plowman et al., 1993). When we tested cross-
reactivity between MSP and HGF, we found a high degree
of specificity, since neither did MSP affect the kinase
activity of the HGF receptor nor was HGF able to stimulate
p185R0N. Moreover, the biological responses triggered by
either HGF or MSP were not reciprocally stimulated or
inhibited.
It has been shown that the minimal portion of the HGF
molecule involved in receptor binding is located within
the first two N-terminal kringles (Matsumoto et al., 1991;
Hartmann et al., 1992; Lokker et al., 1992, 1994; Lokker
and Godowski, 1993). Here we show that this is also the
case for MSP, since a recombinant protein including
only the first two kringles is active in inducing tyrosine
phosphorylation of p185R0N.
This paper demonstrates that p185RON is a tyrosine
kinase receptor responsive to MSP. The intracellular sig-
nals transduced are almost completely unknown. A striking
homology between p1 85R0N and the HGF receptor is
found in the C-terminal tail, a region which is critical for
signal transduction. In this otherwise divergent region of
p1 85R0N two tyrosines are conserved, together with their
surrounding residues (tyrosines 1349 and 1356 of Met,
tyrosines 1353 and 1360 of Ron sequence: Figure 1). We
have recently shown that phosphorylation of these two
tyrosines, both in Met and in Ron generates a docking site
that mediates high affinity interactions with multiple SH2-
containing signal transducers. These include PI 3-kinase,
phospholipase-C-y, pp6ocs?c and the GRB-2/SoS complex
(Ponzetto et al., 1994). This multifunctional docking site
integrates several pathways and it has the potential of
triggering diverse biological responses in target cells:
growth, motility and differentiation (for a review see
Comoglio, 1993). This, together with the wide spectrum of
cell types expressing p1 85R0N, suggest that the biological
function of MSP, originally confined to macrophage migra-
tion, is likely to be far more reaching.
Materials and methods
Cell lines and tissue samples
GTL16 cell line is a clonal cell line derived from a poorly differentiated
gastric carcinoma line (Giordano et al., 1989a). All other cell lines were
from ATCC: A549 (lung carcinoma); SUIT2 and PT45 (pancreatic
carcinoma); K562, U266 and HL-60 (hemopoietic); KATOHI (gastric
carcinoma); HepG2 (hepatocellular carcinoma); DAOY (medulloblas-
toma); T47D (mammary carcinoma). Blood monocytes were purified
from buffy coats from healthy donors by Ficoll density gradient centrifu-
gation and adherence. Normal and neoplastic tissues were harvested
from organ donors and surgical specimens, immediately frozen in liquid
nitrogen, and their RNA was extracted using the single step method of
extraction described by Chomczynski and Sacchi (1987).
Cloning of RON cDNA
Total RNA (10 ,ug) extracted from different epithelial cell lines was
used as a template for synthesis of oligo(dT)-primed double stranded
cDNA, using M-MLV-RT from BRL (UK). PCRs were performed using
degenerate primers based on the amino acid sequences PTVKD and
QPEYC of the subdomains VI and X of tyrosine kinases (Hanks et al.,
1988) and a partial cDNA clone of 384 bp was obtained. The entire
RON cDNA was isolated from a GTL-16 Xgtl 1 cDNA library (Giordano
et al., 1993) by plaque hybridization, using the above cDNA as a probe.
Full-size RON cDNA was subcloned in pBluescript for sequencing,
performed on double stranded plasmids using the dideoxynucleotide
method (Sanger et al., 1977) and T7 DNA polymerase from Pharmacia
(Uppsala, S). Speific oligonucleotide primers were synthesized by
standard phosphoramidite methods with a PCR-Mate 391 DNA
Synthesizer (Applied Biosystem, UK). The RONcDNA was then inserted
into the pMT2 eukaryotic expression vector, which contains the major
late adenovirus promoter and the SV40 origin of replication.
Construction of the TRK-RON chimeric receptor
The cDNA encoding the extracellular domain (bp 1-1344) of the human
high affinity NGF receptor (TRK) (Martin-Zanca et al., 1986) was fused
to the sequence coding for the transmembrane and cytoplasmic regions of
human RON (bp 2903-4228). The resulting hybrid receptor (TRK-RON)
contains the ligand binding domain of the NGF receptor and the tyrosine
kinase domain of RON. The cDNA fragments for the construction of
the chimeric receptor were constructed by PCR amplification, with the
forward (5'-TGCTGCTGCGGTGCCAGGTGGA-3') and the reverse
(5'-GCCACCGATCTAGAACC-TAGGAGTTCGTCCT-3') primers for
TRK and with the forward (5'-AGGTCCAGCGAATTCACTAAGT-
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CAAGT-3') and the reverse (5'-CCACAGTCGACGCTCCTAGGTATC-
CTGC-3') primers for RON. Modified TRK and RON cDNAs were
recombined through the AvrII restriction site. The sequence of the
construct was determined as described above. The chimera was then
inserted into the pMT2 eukaryotic expression vector. Transfection of the
RON, MET (Giordano et al., 1993) and TRK-RON cDNA in COS-l
cells was carried out using the DNA-calcium phosphate coprecipitation
procedure (CellPhect Transfection Kit, Pharmacia).
Cloning of MSP cDNA
A cDNA encoding the full-length MSP was constructed by joining
together cDNAs encoding MSP amino acids 1-340 (clone 5'MSP)
and 341-711 (clone 3'MSP). These cDNAs were isolated by PCR
amplification of cDNA from human liver. Total human liver RNA (10
,ig) was used as a template for reverse transcription using a mixture of
random hexamer and oligo(dT), using M-MLV-RT from BRL (UK). To
obtain clone 5'MSP, a PCR was performed in a volume of 100 gl
containing 10 gd of the RT reaction, using 1 U of Vent DNA polymerase
(New England Biolabs) and 50 pmol of the forward primer (5'-
CAGTGCAGCCTCCAGCCAGAA-3') and the reverse primer (5'-
CTGTACAACGCCGGATCTGGTAG-3'). After 30 cycles of denatura-
tion (95° C, 1 min), annealing (55° C, 45 s) and extension (72° C, 2 min),
2 gl of the PCR were re-amplified with the nested forward primer
(5'-AGGACGAATCCACCATGGGGTGGCTCCCACTCCTGCTGCT-
TCTGACT-3') and the nested reverse primer (5'-CCGGAATTCGAA-
CTTCTGCCGGAACCCCGAC-3'). To obtain clone 3'MSP, forward
primers (5'-CCGGAATlTCGAACTTCTGCCGGAACCCCGAC-3') and
reverse primers (5'-ACGGAATTCCCAAGGCATATGGCATCAA-
GGCT-3') were used. The PCR products were digested with EcoRI,
purified and cloned in the vector pRK7. The sequences of six inserts
amplified from separate PCRs were determined as described above. The
sequences of these clones were identical to the sequence of human MSP
(Yoshimura et al., 1993).
Construction of the MSP-NK2 IgG fusion protein
A partial cDNA containing the N-terminal 268 amino acids of MSP was
fused to a sequence of the human IgG-,yl heavy chain. This was
accomplished by synthesizing complementary oligonucleotides (5'-GAT-
CCGCAGATCGAGCGAGAATTCTGTGACCTGCCGCGGTGCGAGA
CG-3' and 5'-GTGACCGTCTCGCACCGCGGCAGGTCACAGAATT-
CTCGCTCGATCTGCG-3') which were used to link the MSP sequences
through the unique BamHI site in MSP to the BstEII site in human IgG-
gl heavy chain cDNA (Bennett et al., 1991). The resulting construct
contained the coding sequences of amino acids 1-268 of MSP, linker
sequences encoding amino acids Glu, Thr, Val and Thr, followed by the
coding sequences of amino acids 216-443 of human Ig-yl heavy chain.
Sequencing of the construct was carried out as described above.
Expression and purification of MSP and MSP-NK2
cDNAs encoding MSP and MSP-NK2 were inserted into the EBV-
based expression plasmid pCIS.EBON, and stable populations of 293
cells containing these plasmids were established as described (Cachianes
et al., 1993). Media from control cells and MSP transfectants were
treated prior to use with 5% FCS for 1 h at 37° C, in order to allow pro-
MSP processing to the mature two chain form (Wang et al., 1994). For
MSP-NK2 purification, serum-free conditioned media from 293 cells
expressing MSP-NK2 were sterile filtered and citrate buffer (pH 6)
was added to give a final concentration of 100 mM citrate. All purification
procedures were performed at 4° C. The media was loaded onto a HiTrap
Protein A column (Pharmacia, Uppsala, S) equilibrated with 100 mM
citrate (pH 6). Bound protein was eluted in 100 mM citrate, pH 6, 3.5
M MgCI2, 2% (v/v) glycerol. Each fraction was immediately buffer-
exchanged by passage through a PD-10 column (Sephadex G-25) pre-
equilibrated with PBS. The fractions were pooled and concentrated.
Protein concentration was determined both by anti-human Fc ELISA
and by total amino acid hydrolysis. The NH2-terminal sequence of the
purified, mature MSP-NK2 was confirmed by protein sequencing and
protein purity and integrity were assessed by silver staining of
SDS-PAGE gels as well as by Western blotting using an antibody
directed against the human Fc region of IgG1.
Antibodies
Phosphotyrosine monoclonal antibodies were from UBI (Lake Placid,
NY). Met antibodies were raised as described elsewhere (Prat et al.,
1990). Ron antibodies were raised in rabbits immunized with the 41 C-
terminal amino acids expressed as GST fusion protein in the prokaryotic
pGEX2 expression vector. The purification of the fusion protein was
performed by affinity chromatography on glutathione - agarose as
described (Smith and Johnson, 1988).
Tyrosine phosphorylation assays
Immunocomplex kinase assays were performed on immunoprecipitates
made with Ron antibodies from untreated and vanadate treated cells (1
mM, 10 min, 37° C), by incubation in 50 gl of 25 mM HEPES pH 7.4,
5 mM Mn C12, 100 jM DTT, supplemented with 40 ,uM ATP and 10
gCi [y-32P]ATP (specific activity 7.000 Ci/mM, Amersham, UK) for 10
min at room temperature. Proteins were separated on SDS -PAGE. Gels
were alkali treated, dried and exposed for autoradiography.
In vivo tyrosine phosphorylation was evaluated by Western blot with
phosphotyrosine antibodies of immunoprecipitates. Confluent, growth-
arrested T47D cells, or COS-1 cells, 72 h after transfection, were treated
with conditioned medium from 293 cells, either control or MSP-
transfected, or with purified MSP-NK2 at the indicated concentrations
for 10 min at 370C. Cells were lysed in RIPA buffer (20 mM Tris-HCI
pH 7.4, 150 mM NaCl, 5 mM EDTA, 0.1% SDS, 1% Triton X-100, 1%
DOC, 100 jM Na3VO4) containing protease inhibitors, for immunopre-
cipitation.
Biological assays
DNA synthesis was assayed by [6-3H]thymidine incorporation. Con-
fluent, quiescent T47D cells were exposed to increasing dilutions of the
conditioned media from cells transfected with either an empty vector
(EMPTY) or with a vector containing the MSP or the HGF cDNA, for
24 h, then [6-3H]thymidine (28 Ci/mmol, 1 ,uCi/ml) was added in fresh
medium and the cultures further incubated for 18 h. DNA synthesis was
evaluated by [3H]thymidine incorporation into TCA-precipitable
material.
Cell migration assays were performed in blind-well Boyden chambers,
as previously described (Giordano et al., 1993). Briefly, cells were plated
on polycarbonate filters and incubated for 6 h (A-549) or 3 h (monocytes).
Increasing dilutions of conditioned media from cells transfected with
either an empty vector (EMPTY), or with a vector containing the HGF
or MSP cDNA, were added in the bottom chamber, for assaying
chemotaxis of A-549, or in the upper chamber, for assaying stimulation
of monocyte migration towards a chemoattractant (C5a) placed in the
bottom chamber. Cells attached to the upper side of the filters were then
mechanically removed, whilst cells which had migrated to the lower
side were fixed with ethanol, stained with toluidine blue and counted.
Other analytical procedures
Northern blot analysis on tissue and cell lines was performed as described
(Di Renzo et al., 1991). Metabolic labelling with D-[6-3H]glucosamine
(20 Ci/mmol, 100 gCi/ml, Amersham, UK) was performed as previously
described (Giordano et al., 1989b) and labelled proteins were immunopre-
cipitated and visualized by SDS-PAGE, fluorography and autoradio-
graphy with intensifying screens. Domain-selective cell surface
biotinylation was performed as previously described (Crepaldi et al.,
1994b) and biotinylated proteins were immunoprecipitated and visualized
by SDS-PAGE and Western blotting with streptavidin-HRP and
enhanced Chemiluminescence kit (ECL, Amersham, UK).
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